AKT1 and cervical carcinoma: Conversely, in a phase II trial, the combination of the pan-AKT inhibitor GSK2141795 and the MEK inhibitor trametinibobtained no confirmed response in 14 patients with squamous and nonsquamous cell persistent or recurrent carcinoma of the uterine cervix [133].